(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Poland identifies two Ukrainian suspects in railway sabotage blast - 2Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- 3Daily Briefing: A bad flu season gets worse
- 4Dozens injured in Russia after train crashes, overturns
- 510 Natural products to Remember for Your Eating routine for a Better You
- Savvy Watches: Which One Is Appropriate for You?
- When faith comes under fire: How Iran’s repression of religious minorities has increased
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- The Best Music Collections of the 10 years
- Vote In favor of Your Favored Language Interpretation Administration
- 10 Moving Design Frill for Summer 2023
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- Polish law aimed at lowering petrol prices takes effect
- Big majority in Germany call Berlin's efforts on gas prices too weak
